Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Cevimeline hydrochloride
Drug ID BADD_D00425
Description Cevimeline is a parasympathomimetic agent that act as an agonist at the muscarinic acetylcholine receptors M1 and M3. It is indicated by the Food and Drug Administration for the treatment of dry mouth associated with Sjögren's syndrome.
Indications and Usage For the treatment of symptoms of dry mouth in patients with Sjögren's Syndrome.
Marketing Status approved
ATC Code N07AX03
DrugBank ID DB00185
KEGG ID D00661
MeSH ID C059240
PubChem ID 123603
TTD Drug ID D0Q4CS
NDC Product Code 59651-422; 66406-0269; 0054-0334; 0713-0883; 40032-999; 46014-1002; 58159-087; 63395-201; 72888-118; 0713-0937; 42973-228; 72166-012; 43386-999; 16571-657
UNII P81Q6V85NP
Synonyms cevimeline | 2-methyspiro(1,3-oxathiolane-5,3)quinuclidine | AF 102B, (trans)-isomer | AF-102B | AF 102B | AF102B | Evoxac | FKS 508 | FKS-508 | SNI 2011 | SNI-2011 | AF 102B, (cis-(+))-isomer | cevimeline hydrochloride
Chemical Information
Molecular Formula C10H18ClNOS
CAS Registry Number 107220-28-0
SMILES CC1OC2(CN3CCC2CC3)CS1.Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Urine flow decreased20.02.02.012--Not Available
Urticaria23.04.02.001; 10.01.06.001--
Uterine haemorrhage24.07.03.004; 21.07.01.005--
Vaginal discharge21.08.02.002--
Vaginal haemorrhage24.07.03.005; 21.08.01.001--
Vaginal infection21.14.02.002; 11.01.10.002--
Vasculitis24.12.04.027; 10.02.02.006--
Vasodilatation24.03.02.003; 23.06.05.006--Not Available
Vertigo17.02.12.002; 04.04.01.003--
Viral infection11.05.04.001--Not Available
Visual impairment06.02.10.013--Not Available
Vitreous detachment12.01.04.005; 06.09.01.002--Not Available
Vomiting07.01.07.003--
Weight decreased13.15.01.005--
Weight increased13.15.01.006--
Xerophthalmia14.12.03.002; 06.06.03.008--Not Available
Yawning22.12.03.037--Not Available
Multiple sclerosis relapse17.16.01.003--Not Available
Hypoacusis04.02.01.006--
Deep vein thrombosis24.01.02.003--Not Available
Post procedural haemorrhage24.07.01.014; 12.02.05.004--
Thermal burn23.03.11.042; 12.05.04.001--
Affect lability19.04.01.001--Not Available
Rectal tenesmus15.05.03.011; 07.03.03.001--Not Available
Angiopathy24.03.02.007--Not Available
Blood alkaline phosphatase increased13.04.02.004--
Hepatic enzyme increased13.03.04.028--Not Available
Hot flush24.03.01.005; 08.01.03.027; 21.02.02.001--
Bacterial infection11.02.01.005--Not Available
Cardiac disorder02.11.01.003--Not Available
The 12th Page    First    Pre   12 13    Next   Last    Total 13 Pages